Michael NL - Search Results

1

Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans.

Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, Galley L, Karnasuta C, Kim SR, Robb ML, Michael NL, Kibuuka H, Wabwire-Mangen F, Graham BS, Birx DL, de Souza MS, Cox JH. Eller MA, et al. Among authors: michael nl. Vaccine. 2007 Nov 7;25(45):7737-42. doi: 10.1016/j.vaccine.2007.08.056. Epub 2007 Sep 17. Vaccine. 2007. PMID: 17920731 Clinical Trial.

2

HIV neutralization assay using polymerase chain reaction-derived molecular signals.

Robb ML, Polonis V, Vahey M, Gartner S, Michael N, Fowler A, Redfield RR. Robb ML, et al. J Acquir Immune Defic Syndr (1988). 1992 Dec;5(12):1224-9. J Acquir Immune Defic Syndr (1988). 1992. PMID: 1453333

3

Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Michael NL, Chang G, d'Arcy LA, Tseng CJ, Birx DL, Sheppard HW. Michael NL, et al. J Virol. 1995 Nov;69(11):6758-69. doi: 10.1128/JVI.69.11.6758-6769.1995. J Virol. 1995. PMID: 7474087 Free PMC article.

4

Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus.

Michael NL, Chang G, d'Arcy LA, Ehrenberg PK, Mariani R, Busch MP, Birx DL, Schwartz DH. Michael NL, et al. J Virol. 1995 Jul;69(7):4228-36. doi: 10.1128/JVI.69.7.4228-4236.1995. J Virol. 1995. PMID: 7769682 Free PMC article.

5

Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort.

Michael NL, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke DS, Redfield RR, Birx DL, Cassol SA. Michael NL, et al. J Virol. 1995 Mar;69(3):1868-77. doi: 10.1128/JVI.69.3.1868-1877.1995. J Virol. 1995. PMID: 7853528 Free PMC article.

6

Assessment of gag DNA and genomic RNA in peripheral blood mononuclear cells in HIV-infected patients receiving intervention with a recombinant gp 160 subunit vaccine in a phase I study.

Vahey M, Birx DL, Michael NL, Burke DS, Redfield RR. Vahey M, et al. Among authors: michael nl. AIDS Res Hum Retroviruses. 1994 Jun;10(6):649-54. doi: 10.1089/aid.1994.10.649. AIDS Res Hum Retroviruses. 1994. PMID: 8074929 Clinical Trial. No abstract available.

7

Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.

Vancott TC, Polonis VR, Loomis LD, Michael NL, Nara PL, Birx DL. Vancott TC, et al. Among authors: michael nl. AIDS Res Hum Retroviruses. 1995 Nov;11(11):1379-91. doi: 10.1089/aid.1995.11.1379. AIDS Res Hum Retroviruses. 1995. PMID: 8573396

8

V3 seroreactivity and sequence variation: tracking the emergence of V3 genotypic variation in HIV-1-infected patients.

Michael NL, Davis KE, Loomis-Price LD, VanCott TC, Burke DS, Redfield RR, Birx DL. Michael NL, et al. AIDS. 1996 Feb;10(2):121-9. doi: 10.1097/00002030-199602000-00001. AIDS. 1996. PMID: 8838699 Clinical Trial.

9

Summary of track A: basic science.

Birx DL, VanCott T, Michael N, McNeil J, Stamatos N, Gilliam B, Davis R, Carr J, McCutchan F. Birx DL, et al. AIDS. 1996 Dec;10 Suppl 3:S85-106. AIDS. 1996. PMID: 8970716 Review.

10

Evolution of human immunodeficiency virus type 1 env sequence variation in patients with diverse rates of disease progression and T-cell function.

McDonald RA, Mayers DL, Chung RC, Wagner KF, Ratto-Kim S, Birx DL, Michael NL. McDonald RA, et al. Among authors: michael nl. J Virol. 1997 Mar;71(3):1871-9. doi: 10.1128/JVI.71.3.1871-1879.1997. J Virol. 1997. PMID: 9032317 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

455 results

Search Page